Lucentis approved in Japan

Article

Lucentis (ranibizumab; Novartis) has been approved for the treatment of wet age-related macular degeneration (AMD) in Japan, Novartis has announced.

Lucentis (ranibizumab; Novartis) has been approved for the treatment of wet age-related macular degeneration (AMD) in Japan, Novartis has announced.

The application for approval in Japan was supported by a clinical trial demonstrating the efficacy of the anti-vascular endothelial growth factor (anti-VEGF) therapy. The approval comes simultaneously with three other Novartis drug approvals in Japan: Tasigna, for cancer, Xolair for asthma and Co-Dio for high blood pressure.

Lucentis has been approved in Europe since February 2007.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
A flip-calendar shows March 31st as the date, while the United States Food and Drug Administration and European Medicines Agency logos hover above. Image credit: ©Jenn Miranda, via Canva. FDA and EMA logos courtesy respective agencies.

Retina recap: EMA and US FDA approvals, March 2025

Sydney M Crago
April 3rd 2025
Article

Regulatory agencies issued approvals for new treatments and expanded uses of existing therapies in the retina space

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

An image of a person pressing a computer shutdown button, superimposed digitally over the image. Concept for clinical trial discontinuation. Image credit: ©natali_mis – stock.adobe.com

Opthea discontinues COAST and ShORe sozinibercept combination therapy trials

Martin David Harp
April 2nd 2025
Article

Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

An image of the European Medicines Agency (EMA) headquarters to accompany a CHMP opinion. Image credit: ©Lubo Ivanko – stock.adobe.com

EMA grants positive CHMP opinion for low-dose atropine SYD-101 (Ryjunea, Sydnexis)

Hattie Hayes
April 1st 2025
Article

A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary endpoint for slowing paediatric myopia progression

A close-up of a doctor's face. The doctor wears PPE including a mask and safety goggles. Oncology and ophthalmology concept image. Image credit: ©H_Ko – stock.adobe.com

New study investigates ocular involvement in multiple myeloma

Lynda Charters
April 1st 2025
Article

Hematologists and ophthalmologists could work together for earlier diagnoses, research findings indicate

© 2025 MJH Life Sciences

All rights reserved.